Royalty Pharma plc (RPRX) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, Royalty Pharma plc (RPRX) trades at a price-to-earnings ratio of 26.6x, with a stock price of $47.43 and trailing twelve-month earnings per share of $1.37.
The current P/E is 36% below its 5-year average of 41.8x. Over the past five years, RPRX's P/E has ranged from a low of 11.1x to a high of 350.0x, placing the current valuation at the 65th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, RPRX is roughly in line with its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, RPRX trades roughly in line with the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Royalty and IP Monetization Vehicles peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| RPRXRoyalty Pharma plc | $7B | 26.6 | - | -7% |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $773M | 38.9 | - | -83% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $35.28 | $1.75 | 20.1x | -48% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $36.03 | $2.30 | 15.7x | -59% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $31.13 | $2.45 | 12.7x | -67% |
| FY2024 Q4 | $25.51 | $1.92 | 13.3x | -66% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $28.29 | $2.56 | 11.1x | -71% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $26.37 | $1.50 | 17.5x | -55% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $30.37 | $1.78 | 17.0x | -56% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $28.09 | $2.54 | 11.1x | -71% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $27.14 | $0.40 | 67.8x | +75% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $30.74 | $0.56 | 54.4x | +41% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $36.03 | $0.76 | 47.5x | +23% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $39.52 | $0.11 | 350.0x | +805% |
Average P/E for displayed period: 38.7x
See RPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RPRX vs AGIO
See how RPRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RPRX stock overvalued or undervalued?
RPRX trades at 26.6x P/E, below its 5-year average of 41.8x. At the 65th percentile of historical range, the stock is priced at a discount to its own history.
How does RPRX's valuation compare to peers?
Royalty Pharma plc P/E of 26.6x compares to sector median of 23.2x. The premium reflects expected growth above peers.
What is RPRX's PEG ratio?
RPRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2025.